Embed Size (px)
Citation preview
Paul Maguire Enterprise Ireland
Biotechnology Commercialisation in Ireland- Looking to the Future
Federal Lab Consortium (FLC) / Mid-Atlantic Region (MAR)Regional Meeting - September 20th, 2006
Cumberland, Maryland
“To accelerate the development of world-class Irish companies to achieve strong positions in global markets resulting in increased national and
regional prosperity”
12 Offices in Ireland34 Offices Overseasincl. 5 in the USA
ENTERPRISE IRELAND’S KEY ROLE
EI’s US Office Network
South America
Canada
physical office location
4 Employees16 Employees
2 Employees
3 Employees
1 Employees
“Over eight years Ireland has changed dramatically. With changing times and a great deal of success new challenges and new opportunities have arisen. Ireland today has:
The lowest level of unemployment in the EU The second lowest national debt The second highest minimum wage The highest investment in the EU on infrastructure The fastest growth of all OECD countries in spending per capita on health The most generous tax and welfare system in the world for single income
families on the average industrial wage.”
Introduction to the Third Government Progress Report, July 2005
Irelands GDP per Capita
0
10 000
20 000
30 000
40 000
50 000
60 000
OECD
0
1
2
3
4
5
Mex
ico
Slova
k Rep
ublic
Polan
d
Gre
ece
Turke
y
South
Afri
caIndi
a
Portu
gal
Hunga
ry
Brazil
Spain
Italy
New Z
eala
nd
Russia
n Fed
erat
ion
Irelan
d
Czech
Rep
ublic
China
Austra
lia
Norway
Luxe
mbo
urg
Nethe
rland
s
Unite
d Kin
gdom
Belgiu
mEU15
Canad
a
Franc
e
Austri
a
OECD to
tal
Ger
man
y
Switzer
land
Denm
ark
Korea
Unite
d Sta
tes
Icela
nd
Japa
n
Finlan
d
Sweden
R&D Expenditure
1.2
Gross domestic expenditure on R&DAs a percentage of GDP, 2004
2.7
Life Science investment 2000-04
Investment in R&D Base:
€1.3 billion invested in R&D- €645m SFI; €605m HEA.
National Centres
National Centre for BiomedicalEngineering Science NUIG The Bioscience Research Institute
University College Cork
Conway Institute UCDThe Institute of Immunology, located in the Bioscience
Building, NUI Maynooth
The Trinity Centre for BioEngineering (TCBE)
Life-science Companies
•17% Diagnostics
•20% Drug Discovery and Development
•17% Pharmaceuticals and Chemicals
•20% Medical Devices
•26% Services and Support
• Approx. 70 Indigenous Companies
Also- Food industry investing heavily in R&D for functional foods
Diagnostic
Agri-Food
Pharmaceutical Service
Bio-Environmental Services
Pharmaceutical/VaccineBELFAST
DUBLIN
CORK
GALWAY
Clusters of Irish Biotech Companies
No. Cos 5No. Indig. Cos. 3No. of Staff 226No. of R&D Staff 14
No. Cos 8No. Indig. Cos. 4No. of Staff 1050No. of R&D Staff 40
No. Cos 16No. Indig. Cos. 12No. of Staff 829No. of R&D Staff 71
No. Cos 14No. Indig. Cos. 14No. of Staff 538No. of R&D Staff 174
Government Strategy
“High levels of investment in research and innovation are essential in order to become a competitive and dynamic
knowledge-based economy.”
http://www.entemp.ie/publications/science/2006/sciencestrategy.pdf
“Over the life of this Strategy we aim to see a doubling of postgraduate researchers, with significant numbers of these going on to take up employment in the enterprise sector. We also aim to ensure more effective commercialisation of the ideas and know-how being generated in our universities and public research institutions, and to forge new partnerships between these institutions and enterprise.”
Bertie Ahern T.D.Bertie Ahern T.D.
TaoiseachTaoiseach
Prime Minister of IrelandPrime Minister of Ireland
Focus of Strategy
World Class Research Capturing, Protecting and Commercialising Ideas and Know-how Research and Development for Enterprise, Innovation and Growth Science Education and Society Research in the Public Sector All-Island and International STI Implementation
““The creation, exploitation and commercialisation of research are critical if Ireland The creation, exploitation and commercialisation of research are critical if Ireland is to overcome competitive threats and sustain its economic momentum.”is to overcome competitive threats and sustain its economic momentum.”
Technology Transfer
“Transfer of knowledge and technology from higher education institutes into the marketplace is recognised as being of
crucial importance in the establishment of a strong research environment and a knowledge-based economy.”
EI-Bio Supports for Biotech.
EI Bio is building the biotechnology sector through the strategic commercialisation of research in Ireland.
2 approaches to commercializing research:
Funding mechanisms to provide financial support for the development of these technologies.
- support all levels of technology development from proof of concept to commercialisation and beyond.
Commercialization support to help the researcher develop the technology within a commercial context.
- On-campus personnel to support all aspects of IP identification, protection and exploitation.
Intellectual Property
National Code of Practice for Managing Intellectual Property from Publicly Funded Research- 2004
Research Institute owns the IP
National Code of Practice for Managing Intellectual Property from Public-Private Collaborative Research- 2005
Ownership determined by intellectual and financial input and ability to exploit.
Institutional Technology Transfer
Strengthening the Technology Transfer Function (The 3rd Stream)Technology Transfer is the link between Research and the
Market
- Increased funding and support
€30m over 5 years.
Integral part of institutional strategy. Clear realistic goals based on track record. Based on National Codes of Practice. Offices resourced appropriately. Central support provided by EI.
Technology Transfer will only occur when university and industry representatives work together for mutual gain.
- Industry-led networks (€2m)Industry-informed research projects carried out by academia.
- Competence Centres (€10-20m)Long term research programmes in academic centres managed by
industry and academia.
Industry- Academia Linkages
Strategic Emphasis
Increased emphasis on National Approach to capability building.
Overall innovation performance of the economy is not dependant on how specific institutions perform, but rather on how they interact with each other as
elements of a collective system of knowledge creation and use. (OECD 1994)
EI Programmes
Research Community Research Community and Industry
Industry
Policy Approach
To Get a Flow of Commercial Opportunities to Arise from the Research Community
To Facilitate access by companies to Skills and Knowledge in the Research Community
To build firms’ technological capabilities
Programmes Commercialisation Fund Innovation Partnerships RTIR&D AwarenessInnovation Management
International Programmes
Industry-led networks
TechnologyTransfer
Infrastructure Basic Research
State Aid Investment
Questions….?
Paul MaguireSVP Market Development
Enterprise IrelandWashington DC
On behalf of
Paul RobenDirector, Biotechnology Commercialisation
Enterprise [email protected]
Thank You!
